Bicycle Therapeutics (BCYC)
Bicycle Therapeutics Statistics
Share Statistics
Bicycle Therapeutics has 69.06M shares outstanding. The number of shares has increased by 61.99% in one year.
Shares Outstanding | 69.06M |
Shares Change (YoY) | 61.99% |
Shares Change (QoQ) | 0.07% |
Owned by Institutions (%) | 60.72% |
Shares Floating | 61.3M |
Failed to Deliver (FTD) Shares | 5.54K |
FTD / Avg. Volume | 1.59% |
Short Selling Information
The latest short interest is 4.3M, so 6.22% of the outstanding shares have been sold short.
Short Interest | 4.3M |
Short % of Shares Out | 6.22% |
Short % of Float | 9.73% |
Short Ratio (days to cover) | 12.41 |
Valuation Ratios
The PE ratio is -48.21 and the forward PE ratio is -2.08. Bicycle Therapeutics's PEG ratio is 0.51.
PE Ratio | -48.21 |
Forward PE | -2.08 |
PS Ratio | 231.02 |
Forward PS | 1 |
PB Ratio | 10.28 |
P/FCF Ratio | -49.1 |
PEG Ratio | 0.51 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Bicycle Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.81, with a Debt / Equity ratio of 0.01.
Current Ratio | 13.81 |
Quick Ratio | 13.81 |
Debt / Equity | 0.01 |
Debt / EBITDA | -0.02 |
Debt / FCF | -0.02 |
Interest Coverage | -121.31 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $115.66K |
Profits Per Employee | $-554.2K |
Employee Count | 305 |
Asset Turnover | 0.04 |
Inventory Turnover | n/a |
Taxes
Income Tax | -4.76M |
Effective Tax Rate | 2.74% |
Stock Price Statistics
The stock price has increased by -61.76% in the last 52 weeks. The beta is 1.4, so Bicycle Therapeutics's price volatility has been higher than the market average.
Beta | 1.4 |
52-Week Price Change | -61.76% |
50-Day Moving Average | 9.47 |
200-Day Moving Average | 17.97 |
Relative Strength Index (RSI) | 54.13 |
Average Volume (20 Days) | 348.87K |
Income Statement
In the last 12 months, Bicycle Therapeutics had revenue of 35.27M and earned -169.03M in profits. Earnings per share was -0.29.
Revenue | 35.27M |
Gross Profit | 35.27M |
Operating Income | -209.87M |
Net Income | -169.03M |
EBITDA | -164.89M |
EBIT | -172.07M |
Earnings Per Share (EPS) | -0.29 |
Balance Sheet
The company has 879.52M in cash and 3.99M in debt, giving a net cash position of 875.53M.
Cash & Cash Equivalents | 879.52M |
Total Debt | 3.99M |
Net Cash | 875.53M |
Retained Earnings | -680.79M |
Total Assets | 956.87M |
Working Capital | 861.38M |
Cash Flow
In the last 12 months, operating cash flow was -164.72M and capital expenditures -1.24M, giving a free cash flow of -165.96M.
Operating Cash Flow | -164.72M |
Capital Expenditures | -1.24M |
Free Cash Flow | -165.96M |
FCF Per Share | -0.29 |
Margins
Gross margin is 100%, with operating and profit margins of -594.96% and -479.18%.
Gross Margin | 100% |
Operating Margin | -594.96% |
Pretax Margin | -492.69% |
Profit Margin | -479.18% |
EBITDA Margin | -467.45% |
EBIT Margin | -594.96% |
FCF Margin | -470.47% |
Dividends & Yields
BCYC does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for BCYC is $28, which is 223% higher than the current price. The consensus rating is "Buy".
Price Target | $28 |
Price Target Difference | 223% |
Analyst Consensus | Buy |
Analyst Count | 9 |
Scores
Altman Z-Score | 1.68 |
Piotroski F-Score | 4 |